Charlotte Reed speaks with Mike Doustdar, CEO of Novo Nordisk, after the Danish comapny hiked its 2026 full-year guidance on the back of increased expectations for GLP-1 product sales.
Source
Novo Nordisk CEO: Aim is to expand weight-loss market in U.S.
World
CVS blows past estimates, hikes outlook as insurance business outperforms
A screen displays the logo and trading information for CVS at the New York Stock Exchange, March 24, 2026. Jeenah Moon | Reuters CVS Health on Wednesday blew past first-quarter earnings and revenue estimates and raised its 2026 guidance, as its once-troubled insurance business showed improvement. CVS, which operates the nation’s largest pharmacy chain, sees […]
Read More
World
European stocks soar amid growing optimism for Gulf peace deal
European stocks soared on Wednesday as traders responded to reports that the U.S. and Iran are close to an agreement that will bring an end to the war. The White House expects an Iranian response on “several key points”, including a moratorium on nuclear enrichment, in the next 48 hours, Axios reported. The countries are […]
Read More
World
Novo Nordisk stock jumps 6% after drugmaker hikes forcast as Wegovy pill sales smash forecasts
People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in Copenhagen, Denmark, March 26, 2026. Tom Little | Reuters Novo Nordisk hiked its annual profit guidance on Wednesday, as the drugmaker said its Wegovy weight-loss pill performed better than expected in the first three months of the […]
Read More